iShares Biotechnology ETF
597 hedge funds and large institutions have $5.25B invested in iShares Biotechnology ETF in 2019 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 128 increasing their positions, 269 reducing their positions, and 96 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
36% less funds holding in top 10
Funds holding in top 10: 14 → 9 (-5)
49% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 96
52% less repeat investments, than reductions
Existing positions increased: 128 | Existing positions reduced: 269
Holders
597
Holding in Top 10
9
Calls
$509M
Puts
$707M
Top Buyers
| 1 | +$300M | |
| 2 | +$235M | |
| 3 | +$83.1M | |
| 4 |
JPMorgan Chase & Co
New York
|
+$67.7M |
| 5 |
Goldman Sachs
New York
|
+$65.4M |
Top Sellers
| 1 | -$361M | |
| 2 | -$46.3M | |
| 3 | -$45.5M | |
| 4 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$44.6M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$40.1M |